Cargando…
Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial
BACKGROUND: Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with rega...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041082/ https://www.ncbi.nlm.nih.gov/pubmed/36993916 http://dx.doi.org/10.1016/j.hroo.2022.12.008 |
_version_ | 1784912628014907392 |
---|---|
author | Demidova, Marina M. Rylance, Rebecca Koul, Sasha Dworeck, Christian James, Stefan Aasa, Mikael Hamid, Mehmet Swahn, Eva Hambraeus, Kristina Danielewicz, Mikael Linder, Rikard Fröbert, Ole Grimfjärd, Per Stewart, Jason Henareh, Loghman Andersson, Jonas Wagner, Henrik Erlinge, David Platonov, Pyotr G. |
author_facet | Demidova, Marina M. Rylance, Rebecca Koul, Sasha Dworeck, Christian James, Stefan Aasa, Mikael Hamid, Mehmet Swahn, Eva Hambraeus, Kristina Danielewicz, Mikael Linder, Rikard Fröbert, Ole Grimfjärd, Per Stewart, Jason Henareh, Loghman Andersson, Jonas Wagner, Henrik Erlinge, David Platonov, Pyotr G. |
author_sort | Demidova, Marina M. |
collection | PubMed |
description | BACKGROUND: Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with regard to reperfusion, or type of arrhythmia. OBJECTIVE: We analyzed the prognostic value of early ventricular arrhythmias (VAs) in STEMI with regard to their type and timing. METHODS: The prespecified analysis of the multicenter prospective Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarctionin Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease evaluated according to Recommended Therapies Registry Trial included 2886 STEMI patients undergoing primary percutaneous coronary intervention (PCI). VA episodes were characterized regarding their type and timing. Survival status at 180 days was assessed through the population registry. RESULTS: Nonmonomorphic VT or VF was observed in 97 (3.4%) and monomorphic VT in 16 (0.5%) patients. Only 3 (2.7%) early VA episodes occurred after 24 hours from symptom onset. VA was associated with higher risk of death (hazard ratio 3.59; 95% confidence interval [CI] 2.01–6.42) after adjustment for age, sex, and STEMI localization. VA after PCI was associated with an increased mortality compared with VA before PCI (hazard ratio 6.68; 95% CI 2.90–15.41). Early VA was associated with in-hospital mortality (odds ratio 7.39; 95% CI 3.68–14.83) but not with long-term prognosis in patients discharged alive. The type of VA was not associated with mortality. CONCLUSION: VA after PCI was associated with an increased mortality compared with VA before PCI. Long-term prognosis did not differ between patients with monomorphic VT and nonmonomorphic VT or VF, but events were few. VA incidence during 24 to 48 hours of STEMI is negligibly low, thus precluding assessment of its prognostic importance. |
format | Online Article Text |
id | pubmed-10041082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100410822023-03-28 Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial Demidova, Marina M. Rylance, Rebecca Koul, Sasha Dworeck, Christian James, Stefan Aasa, Mikael Hamid, Mehmet Swahn, Eva Hambraeus, Kristina Danielewicz, Mikael Linder, Rikard Fröbert, Ole Grimfjärd, Per Stewart, Jason Henareh, Loghman Andersson, Jonas Wagner, Henrik Erlinge, David Platonov, Pyotr G. Heart Rhythm O2 Clinical BACKGROUND: Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with regard to reperfusion, or type of arrhythmia. OBJECTIVE: We analyzed the prognostic value of early ventricular arrhythmias (VAs) in STEMI with regard to their type and timing. METHODS: The prespecified analysis of the multicenter prospective Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarctionin Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease evaluated according to Recommended Therapies Registry Trial included 2886 STEMI patients undergoing primary percutaneous coronary intervention (PCI). VA episodes were characterized regarding their type and timing. Survival status at 180 days was assessed through the population registry. RESULTS: Nonmonomorphic VT or VF was observed in 97 (3.4%) and monomorphic VT in 16 (0.5%) patients. Only 3 (2.7%) early VA episodes occurred after 24 hours from symptom onset. VA was associated with higher risk of death (hazard ratio 3.59; 95% confidence interval [CI] 2.01–6.42) after adjustment for age, sex, and STEMI localization. VA after PCI was associated with an increased mortality compared with VA before PCI (hazard ratio 6.68; 95% CI 2.90–15.41). Early VA was associated with in-hospital mortality (odds ratio 7.39; 95% CI 3.68–14.83) but not with long-term prognosis in patients discharged alive. The type of VA was not associated with mortality. CONCLUSION: VA after PCI was associated with an increased mortality compared with VA before PCI. Long-term prognosis did not differ between patients with monomorphic VT and nonmonomorphic VT or VF, but events were few. VA incidence during 24 to 48 hours of STEMI is negligibly low, thus precluding assessment of its prognostic importance. Elsevier 2022-12-22 /pmc/articles/PMC10041082/ /pubmed/36993916 http://dx.doi.org/10.1016/j.hroo.2022.12.008 Text en © 2022 Heart Rhythm Society. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Clinical Demidova, Marina M. Rylance, Rebecca Koul, Sasha Dworeck, Christian James, Stefan Aasa, Mikael Hamid, Mehmet Swahn, Eva Hambraeus, Kristina Danielewicz, Mikael Linder, Rikard Fröbert, Ole Grimfjärd, Per Stewart, Jason Henareh, Loghman Andersson, Jonas Wagner, Henrik Erlinge, David Platonov, Pyotr G. Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial |
title | Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial |
title_full | Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial |
title_fullStr | Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial |
title_full_unstemmed | Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial |
title_short | Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial |
title_sort | prognostic value of early sustained ventricular arrhythmias in st-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a substudy of validate-swedeheart trial |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041082/ https://www.ncbi.nlm.nih.gov/pubmed/36993916 http://dx.doi.org/10.1016/j.hroo.2022.12.008 |
work_keys_str_mv | AT demidovamarinam prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT rylancerebecca prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT koulsasha prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT dworeckchristian prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT jamesstefan prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT aasamikael prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT hamidmehmet prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT swahneva prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT hambraeuskristina prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT danielewiczmikael prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT linderrikard prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT frobertole prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT grimfjardper prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT stewartjason prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT henarehloghman prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT anderssonjonas prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT wagnerhenrik prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT erlingedavid prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial AT platonovpyotrg prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial |